The Drug Safety Newsletter is a source of information for healthcare professionals about the findings of selected postmarketing drug safety reviews from FDA's Center for Drug Evaluation and Research (CDER). The Newsletter also provides information on important emerging drug safety issues and recently approved new molecular entities. The Newsletter is expected to be published quarterly. Launched in September 2007, the Drug Safety Newsletter is produced by CDER's Safety Policy and Communication Staff. It is one of FDA's tools to communicate evolving safety information about pharmaceutical products regulated by CDER.

Click Here to go to the Newsletter Homepage. The inaugural issue is available online now! On the left hand side you can also subscribe free to the newsletter.